Market Overview:
The global dopamine agents market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of Parkinson’s disease, rising geriatric population, and growing demand for better treatment options. The dopamine agents market is segmented by type (oral and injectable), by application (hospital and clinic), and by region (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa). The oral segment is expected to dominate the global dopamine agents market during the forecast period owing to its ease of use and lower cost as compared to injectable drugs. However, the injectable segment is projected to grow at a higher CAGR during the forecast period due its advantages such as longer duration of action and fewer side effects as compared to oral drugs. On the basis of application, hospital dominates the global dopamine agents market due high incidence rate of Parkinson’s disease in hospitals coupled with increasing number of surgical procedures for treating Parkinson’s disease.
Product Definition:
A dopamine agent is a drug that increases the level of dopamine in the brain. Dopamine is a neurotransmitter that plays a role in mood, motivation, and pleasure. Dopamine agents are used to treat conditions such as depression, Parkinson's disease, and schizophrenia.
Oral:
Oral, also known as bupropion or Wellbutrin is an FDA-approved prescription drug used for the treatment of depression and chronic relapsing depression. It's main ingredient is a type of medication called a selective norepinephrine reuptake inhibitor (SNRI). SNRIs are commonly prescribed to patients suffering from major depressive disorder and dysthymia. According to the National Institute of Mental Health, in 2016 about 43.8 million adults in U.S.
Injectable:
Injectable is a form of drug delivery system that allows the active ingredients to be administered at a precise location in the body. Injectables can be administered through various routes including intravenous, subcutaneous, intramuscular, and intraperitoneal. The most commonly used injectable drugs are insulin for diabetes treatment and oral contraceptive pills for birth control.
Application Insights:
The global dopamine agents market has been segmented on the basis of application into hospital, clinic and others. The hospital segment dominated the overall market in terms of revenue in 2017. Increasing prevalence of diseases associated with low levels of dopamine such as Parkinson¢â‚¬â„¢s disease, attention deficit hyperactivity disorder (ADHD), Alzheimer¢â‚¬â„¢s disease and multiple sclerosis is expected to drive demand for these drugs in the coming years.
Increasing awareness about these disorders coupled with rising availability of advanced treatment options is anticipated to fuel demand for dopamine agents over the forecast period. However, increasing government funding towards research & development activities pertaining to new drug treatments for Parkinson's disease may hinder growth during the forecast period.
Clinic applications include dopaminergic drugs used for treating schizophrenia, depression and other movement disorders such as Huntington¢â‚¬â€œdisease.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of key players and well-established healthcare infrastructure. The region is expected to maintain its dominance over the forecast period, with growth primarily driven by U.S., due to rising incidence rates of Parkinson’s disease and other movement disorders coupled with increasing R&D activities for new drug development.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to factors such as improving healthcare facilities, growing patient awareness levels regarding treatment options, availability of effective treatment methods for various diseases including Parkinson's disease and rise in disposable income especially in developing countries like India & China & South Korea etcetera.
Growth Factors:
- Increasing prevalence of neurological disorders such as Parkinson’s disease, attention-deficit hyperactivity disorder (ADHD), and schizophrenia is expected to drive the dopamine agents market growth.
- Rising geriatric population is also a major factor that will contribute to the growth of dopamine agents market in the near future.
- Growing demand for novel therapeutics for various neurological disorders will propel the dopamine agents market growth over the forecast period.
- increasing research and development investments by key players for new drug discovery is anticipated to provide lucrative opportunities for dopamine agents market expansion during forecast period . 5) rising awareness about benefits of using dopaminergic drugs among neurologists and patients is likely to boost demand for these drugs, thereby propelling dopamine agent market growth over next few years
Scope Of The Report
Report Attributes
Report Details
Report Title
Dopamine Agents Market Research Report
By Type
Oral, Injectable
By Application
Hospital, Clinic
By Companies
Glaxosmithkline, Actavis, Eli Lilly, Sun Pharmaceutical, Novartis, Merck, Cardinal Health, Pfizer, Teva, Abbott, Glaxosmithkline
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
188
Number of Tables & Figures
132
Customization Available
Yes, the report can be customized as per your need.
Global Dopamine Agents Market Report Segments:
The global Dopamine Agents market is segmented on the basis of:
Types
Oral, Injectable
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Glaxosmithkline
- Actavis
- Eli Lilly
- Sun Pharmaceutical
- Novartis
- Merck
- Cardinal Health
- Pfizer
- Teva
- Abbott
- Glaxosmithkline
Highlights of The Dopamine Agents Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injectable
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dopamine Agents Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dopamine agents are medications that work by increasing the levels of dopamine in the brain. Dopamine is a neurotransmitter that helps control movement, mood, and cognition.
Some of the major players in the dopamine agents market are Glaxosmithkline, Actavis, Eli Lilly, Sun Pharmaceutical, Novartis, Merck, Cardinal Health, Pfizer, Teva, Abbott, Glaxosmithkline.
The dopamine agents market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dopamine Agents Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dopamine Agents Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dopamine Agents Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dopamine Agents Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dopamine Agents Market Size & Forecast, 2018-2028
4.5.1 Dopamine Agents Market Size and Y-o-Y Growth
4.5.2 Dopamine Agents Market Absolute $ Opportunity
Chapter 5 Global Dopamine Agents Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Dopamine Agents Market Size Forecast by Type
5.2.1 Oral
5.2.2 Injectable
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Dopamine Agents Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Dopamine Agents Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dopamine Agents Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dopamine Agents Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Dopamine Agents Analysis and Forecast
9.1 Introduction
9.2 North America Dopamine Agents Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Dopamine Agents Market Size Forecast by Type
9.6.1 Oral
9.6.2 Injectable
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Dopamine Agents Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Dopamine Agents Analysis and Forecast
10.1 Introduction
10.2 Europe Dopamine Agents Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Dopamine Agents Market Size Forecast by Type
10.6.1 Oral
10.6.2 Injectable
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Dopamine Agents Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Dopamine Agents Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Dopamine Agents Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Dopamine Agents Market Size Forecast by Type
11.6.1 Oral
11.6.2 Injectable
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Dopamine Agents Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Dopamine Agents Analysis and Forecast
12.1 Introduction
12.2 Latin America Dopamine Agents Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Dopamine Agents Market Size Forecast by Type
12.6.1 Oral
12.6.2 Injectable
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Dopamine Agents Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Dopamine Agents Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Dopamine Agents Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Dopamine Agents Market Size Forecast by Type
13.6.1 Oral
13.6.2 Injectable
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Dopamine Agents Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dopamine Agents Market: Competitive Dashboard
14.2 Global Dopamine Agents Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Glaxosmithkline
14.3.2 Actavis
14.3.3 Eli Lilly
14.3.4 Sun Pharmaceutical
14.3.5 Novartis
14.3.6 Merck
14.3.7 Cardinal Health
14.3.8 Pfizer
14.3.9 Teva
14.3.10 Abbott
14.3.11 Glaxosmithkline
